Subscribe To

Price Alert Latest News Economic Calendar News

RAPT / Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 66.77%: Read This Before Placing a Bet

The mean of analysts' price targets for Rapt Therapeutics (RAPT) points to a 66.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. Read More

Demo Live Account See Partner Details

Content Topics

Wall

Street

Analysts

Think

RAPT

Therapeutics

Could

rapt

66 77

Before

Placing

Stock

Posted: Feb 10 2023, 11:18

Author Name: Zacks Investment Research

RAPT News

By Seeking Alpha
June 13, 2023

RAPT Therapeutics: Major Catalysts Are A Long Way Off

RAPT Therapeutics has solid data from early trials but has a habit of going down on good data. One reason could be that the stock is heavily instituti

By Seeking Alpha
March 30, 2023

RAPT Therapeutics: Potential Strong Upside Ahead

RAPT Therapeutics, Inc. is a clinical-stage biotech developer of specific small molecules that can modulate the critical immune drivers of inflammator

By Zacks Investment Research
February 10, 2023

Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 66.77%: Read This Before Placing a Bet

The mean of analysts' price targets for Rapt Therapeutics (RAPT) points to a 66.8% upside in the stock. While this highly sought-after metric has not

By Zacks Investment Research
January 25, 2023

Here's Why 'Trend' Investors Would Love Betting on Rapt Therapeutics (RAPT)

Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the mov

By GlobeNewsWire
November 30, 2022

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-s

By Zacks Investment Research
November 22, 2022

Why RAPT Therapeutics (RAPT) Stock Might be a Great Pick

RAPT Therapeutics (RAPT) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.